

From: Smith, Michael (CBER)
Sent: Tuesday, June 29, 2021 3:47 PM
To: Harkins Tull, Elisa <Elisa.HarkinsTull@pfizer.com>; Aghajani Memar, Neda <Neda.AghajaniMemar@pfizer.com>; Devlin, Carmel M <Carmel.Devlin@pfizer.com>
Cc: Naik, Ramachandra <Ramachandra.Naik@fda.hhs.gov>; Gottschalk, Laura <Laura.Gottschalk@fda.hhs.gov>
Subject: STN 125742.0: Clinical IR RE Study C4591001

Elisa,

The clinical team has the below IR regarding Study C4591001. The review team would prefer a response by July 2, 2021.

Please provide the maximum date (latest date) of randomization for participants included in the reactogenicity subset for Study C4591001. Our evaluation of the datasets indicates that the maximum date of randomization (RANDDT) and vaccination date 01 (VAX101DT) for participants included in the reactogenicity subset is January 8, 2021. If based on your analyses, this date should be different, please provide guidance to the datasets and the appropriate flags we can use to confirm your results within the datasets.

Regards,

Mike

- Please confirm receipt of this e-mail and let us know if you have any questions.

Mike Smith, Ph.D.
Captain, USPHS

Senior Regulatory Review Officer
Food and Drug Administration
Center for Biologics Evaluation & Research
Office of Vaccines Research & Review
Division of Vaccines and Related Products Applications
Tel: 301-796-2640
michael.smith2@fda.hhs.gov



THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.